Polyrizon Ltd. announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. These studies will evaluate the company’s proprietary Trap and Target™ (T&T) platform for Naloxone administration.
The preclinical studies will assess key parameters including drug loading capacity, release kinetics, nasal deposition, and stability. This work lays the groundwork for further safety and efficacy testing in subsequent preclinical and clinical studies.
Tomer Izraeli, CEO of Polyrizon, emphasized the importance of improving Naloxone administration in the face of the global opioid crisis. The T&T platform aims to enhance intranasal Naloxone by offering higher bioavailability and optimized drug release profiles, which could make a critical difference in emergency overdose situations. The global Naloxone market is projected to reach $2.47 billion by 2032, with the intranasal spray market alone expected to reach $1.4 billion by 2030.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.